For example, the presence of IDH1 mutations and 1p/19q co-deletions are associated with better survival outcomes for grade II, III, and IV gliomas [7,23,26,27], which may be relevant for determining treatment options for lower grade glioma patients with worse prognoses [7,26]. Here, IDH1 is linked to glioma.